Function-Blocking Integrin α11β1 Antibodies for Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no approved targeted therapy with disease-modifying potential for fibrotic disorders and cancers, particularly due to the lack of understanding of the mechanisms driving fibrosis and the overexpression of integrin alpha 11 beta 1 (α11β1) in these conditions.
Innovation Solution
Development of novel function-blocking antibodies against type I collagen receptor integrin alpha 11 beta 1 (α11β1) to inhibit its interaction with collagen in human α11β1-expressing cells, reducing fibrosis and cancer progression by targeting key drivers of fibrotic phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no targeted therapy is developed, then current treatment options remain limited, but disease-modifying potential is not achieved
Solution Approach 1:
The patent identifies and targets integrin α11β1 as a key driver of fibrosis before the disease progresses to irreversible stages. By developing antibodies that specifically block this integrin-collagen interaction, the therapy prevents fibrotic phenotypes from establishing, thereby achieving disease-modifying potential rather than just managing symptoms
Solution Approach 2:
The patent uses monoclonal antibodies as intermediary molecules to block the interaction between integrin α11β1 and type I collagen. These antibodies serve as mediators that specifically bind to the integrin receptor, preventing the pathological signaling cascade that leads to fibrosis, while allowing other physiological functions to continue
2Object-affected harmful factors
If integrin alpha 11 beta 1 is targeted to reduce fibrosis, then fibrotic phenotypes are attenuated, but potential off-target effects may occur
Solution Approach 1:
The patent employs antibodies with high specificity for integrin α11β1, ensuring that the therapeutic effect is localized to fibrotic tissues where this integrin is overexpressed. The antibodies bind preferentially to the pathological integrin-collagen interaction sites, attenuating fibrotic phenotypes while leaving other tissues and physiological processes unaffected
Solution Approach 2:
The patent utilizes antibodies with optimized binding affinity parameters for integrin α11β1. By carefully selecting and engineering antibodies with specific kinetic and thermodynamic properties, the therapy achieves effective blockade of fibrotic signaling while maintaining selectivity and minimizing off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively reduce fibrosis and cancer progression by inhibiting myofibroblast differentiation and extracellular matrix deposition, offering a mechanism for local attenuation of fibrosis and modifying disease progression.
Implementation Method 1
novel, function-blocking antibodies against type I collagen receptor integrin alpha 11 beta 1 (α11β1)
Data Source
AI summary
The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 (α11β1), as well as methods of making and using such antibodies.